Accessibility Menu
 
Assembly Biosciences logo

Assembly Biosciences

(NASDAQ) ASMB

Current Price$27.43
Market Cap$439.40M
Since IPO (2010)-93%
5 Year-48%
1 Year+154%
1 Month-6%

Assembly Biosciences Financials at a Glance

Market Cap

$439.40M

Revenue (TTM)

$72.30M

Net Income (TTM)

$6.12M

EPS (TTM)

$-1.84

P/E Ratio

-15.07

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$27.43

Volume

2,666

Open

$28.64

Previous Close

$27.43

Daily Range

$27.29 - $28.80

52-Week Range

$7.75 - $39.70

ASMB: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Assembly Biosciences

Industry

Biotechnology

Employees

73

CEO

Jason A. Okazaki

Headquarters

South San Francisco, CA 94080, US

ASMB Financials

Key Financial Metrics (TTM)

Gross Margin

78%

Operating Margin

-17%

Net Income Margin

-8%

Return on Equity

-5%

Return on Capital

-6%

Return on Assets

-2%

Earnings Yield

-6.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$439.40M

Shares Outstanding

15.86M

Volume

2.67K

Short Interest

0.00%

Avg. Volume

98.57K

Financials (TTM)

Gross Profit

$72.17M

Operating Income

$12.12M

EBITDA

$11.99M

Operating Cash Flow

$41.09M

Capital Expenditure

$66.00K

Free Cash Flow

$41.16M

Cash & ST Invst.

$248.11M

Total Debt

$2.63M

Assembly Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$42.47M

+477.3%

Gross Profit

$42.44M

+713.0%

Gross Margin

99.92%

N/A

Market Cap

$439.40M

N/A

Market Cap/Employee

$6.02M

N/A

Employees

73

N/A

Net Income

$22.09M

+313.7%

EBITDA

$19.83M

+272.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$245.48M

+125.2%

Accounts Receivable

$974.00K

+143.5%

Inventory

$0.00

N/A

Long Term Debt

$2.06M

-21.7%

Short Term Debt

$569.00K

+23.4%

Return on Assets

-2.38%

N/A

Return on Invested Capital

-5.80%

N/A

Free Cash Flow

$14.21M

+3592.1%

Operating Cash Flow

$14.24M

+3598.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NAUTNautilus Biotechnology, Inc.
$3.48-7.94%
ZURAZura Bio Limited
$5.93-1.82%
ENTAEnanta Pharmaceuticals, Inc.
$12.18-2.64%
FHTXFoghorn Therapeutics Inc.
$4.50-8.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About ASMB

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.